A Review of the Evidence for the U.S. Preventive Services Task Force
References
1. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the
U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-8. [PMID: 16732006]
2. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-24. [PMID: 9571335]
3. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, et al. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according
to obesity levels in the U.S. Diabetes Care 2004;27:2806-12. [PMID: 15562189]
4. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81:1158-62. [PMID: 1951827]
5. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-9. [PMID: 1516497]
6. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA
1988;260:2864-71. [PMID: 3184351]
7. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in
Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-63. [PMID: 11270671]
8. Younis N, Broadbent DM, Vora JP, Harding SP. Liverpool Diabetic Eye Study. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361:195-200. [PMID: 12547541]
9. Henricsson M, Tyrberg M, Heijl A, Janzon L. Incidence of blindness and visual impairment in diabetic patients participating in an ophthalmological control and screening programme. Acta Ophthalmol Scand 1996;74:533-8. [PMID: 9017036]
10. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002;25:1129-34. [PMID: 12087009]
11. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care
1999;22:233-40. [PMID: 10333939]
12. Chowdhury TA, Lasker SS. Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes. QJM 2002;95:241-6. [PMID: 11937651]
13. Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986;123:504-16. [PMID: 3946397]
14. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for
coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8. [PMID: 2338751]
15. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulindependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990;131:443-53. [PMID: 2301354]
16. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998;128:524-33. [PMID: 9518396]
17. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ
18. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L,
et al. Adverse prognostic significance of new diabetes in treated hypertensive
subjects. Hypertension 2004;43:963-9. [PMID: 15037557]
19. Niskanen L, Turpeinen A, Penttila¨ I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care
1998;21:1861-9. [PMID: 9802734]
20. Taubert G, Winkelmann BR, Schleiffer T, Marz W, Winkler R, Gok R, et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus
in 3266 patients scheduled for coronary angiography. Am Heart J 2003;145:285-91. [PMID: 12595846]
21. Vancheri F, Curcio M, Burgio A, Salvaggio S, Gruttadauria G, Lunetta MC, et al. Impaired glucose metabolism in patients with acute stroke and no
previous diagnosis of diabetes mellitus. QJM 2005;98:871-8. [PMID: 16239309]
22. Rathmann W, Icks A, Haastert B, Giani G, Lowel H, Mielck A. Undiagnosed diabetes mellitus among patients with prior myocardial infarction. Z Kardiol 2002;91:620-5. [PMID: 12426825]
23. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4. [PMID: 12090978]
24. Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in
Communities (ARIC) Study. Lancet Neurol 2005;4:821-6. [PMID: 16297840]
25. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without
diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005;165:1910-6. [PMID: 16157837]
26. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31. [PMID: 15381515]
27. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38. [PMID: 16824829]
28. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993;16:642-52. [PMID: 8462395]
29. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive
Services Task Force. Ann Intern Med 2003;138:215-29. [PMID: 12558362]
30. Harris RP, Lux LJ, Bunton AJ, Sutton SF, Lohr KN, Donahue KP, et al. Screening for Type 2 Diabetes Mellitus. (Prepared by RTI International Evidence-based Practice Center under contract 290-97-0011 for the Agency for Healthcare Research and Quality.) Rockville, MD: U.S. Department of Health and Human Services; February 2003. Systematic Evidence Review no. 19.
31. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. Ann Intern Med 2003;138:212-4. [PMID: 12558361]
32. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the
process. Am J Prev Med 2001;20:21-35. [PMID: 11306229]
33. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991;44:1271-8. [PMID: 1834807]
34. National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute for Health and Clinical Excellence; 2006.
35. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling.
Health Technol Assess 2007;11:iii-iv, ix-xi, 1-125. [PMID: 17462167]
36. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. [PMID: 11832527]
37. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen
A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to
type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6. [PMID: 10809036]
38. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67:152-62. [PMID: 15649575]
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. [PMID: 3802833]
40. Schellhase KG, Koepsell TD, Weiss NS, Wagner EH, Reiber GE. Glucose screening and the risk of complications in Type 2 diabetes mellitus. J Clin Epidemiol 2003;56:75-80. [PMID: 12589873]
41. Olafsdottir E, Andersson DK, Stefansson E. Visual acuity in a population with regular screening for type 2 diabetes mellitus and eye disease. Acta Ophthalmol Scand 2007;85:40-5. [PMID: 17244208]
42. Agarwal S, Raman R, Kumari RP, Deshmukh H, Paul PG, Gnanamoorthy P, et al. Diabetic retinopathy in type II diabetics detected by targeted screening
versus newly diagnosed in general practice. Ann Acad Med Singapore 2006;35:531-5. [PMID: 17006579]
43. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. The cost-effectiveness of screening for type 2 diabetes.
JAMA 1998;280:1757-63. [PMID: 9842951]
44. Goyder EC, Irwig LM. Screening for type 2 diabetes mellitus: a decision analytic approach. Diabet Med 2000;17:469-77. [PMID: 10975217]
45. Hofer TP, Vijan S, Hayward RA. Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 2000;16:822-33. [PMID: 11028137]
46. Chen TH, Yen MF, Tung TH. A computer simulation model for costeffectiveness analysis of mass screening for type 2 diabetes mellitus. Diabetes Res
Clin Pract 2001;54 Suppl 1:S37-42. [PMID: 11580967]
47. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689-99. [PMID: 15126252]
48. Glumer C, Yuyun M, Griffin S, Farewell D, Spiegelhalter D, Kinmonth AL, et al. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006;49:1536-44. [PMID: 16752172]
49. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G, et al. The ADDITION study: proposed trial of the cost-effectiveness
of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24 Suppl 3:S6-11. [PMID: 11063279]
50. The ALLHAT Officers. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007. [PMID: 12479764]
51. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9. [PMID: 15983290]
52. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82. [PMID: 12709465]
53. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. [PMID: 11937178]
54. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the
Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10. [PMID: 11937179]
55. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. [PMID: 12686036]
56. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7. [PMID: 15855581]
57. 57. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled
trial. Lancet 2003;361:2005-16. [PMID: 12814710]
58. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30. [PMID: 12457784]
59. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-72. [PMID: 14633812]
60. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular
disease in women. N Engl J Med 2005;352:1293-304. [PMID: 15753114]
61. Olivarius NF, Beck-Nielsen H, Andreasen AH, Hørder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001;323:970-5. [PMID: 11679387]
62. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment
and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. [PMID: 9742976]
63. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular
events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-9. [PMID: 15983291]
64. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. [PMID: 10675071]
65. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S, et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of
the HOPE study extension. Circulation 2005;112:1339-46. [PMID: 16129815]
66. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62. [PMID: 9635947]
67. Action to control cardiovascular risk in diabetes (ACCORD) [clinical trial]. ClinicalTrials.gov identifier: NCT00000620. Accessed on 8 April 2008 at www.clinicaltrials.gov/ct2/show/NCT00000620?term=NCT00000620&rank=1.
68. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-24. [PMID: 16585050]
69. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. [PMID: 11786451]
70. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991;98:741-56.
[PMID: 2062510]
71. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35. [PMID: 2664509]
72. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7. [PMID: 12086760]
73. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, et al. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62. [PMID: 16980380]
74. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005;28:888-94.
[PMID: 15793191]
75. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105. [PMID: 16997664]
76. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50. [PMID: 11333990]
77. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-97. [PMID: 16391903]
78. Watanabe M, Yamaoka K, Yokotsuka M, Tango T. Randomized controlled trial of a new dietary education program to prevent type 2 diabetes in a high-risk group of Japanese male workers. Diabetes Care 2003;26:3209-14. [PMID: 14633803]
79. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 2001;24:619-24. [PMID: 11315819]
80. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44. [PMID: 9096977]
81. Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC. The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 1997;46:50-5. [PMID: 9439560]
82. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle
intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9. [PMID: 17098085]
83. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of
orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in
obese patients. Diabetes Care 2004;27:155-61. [PMID: 14693982]
84. Pan CY, Gao Y, Chen JW, Luo BY, Fu ZZ, Lu JM, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2003;61:183-90. [PMID: 12965108]
85. Zinman B, Hoogwerf BJ, Dura´n Garci´a S, Milton DR, Giaconia JM, Kim DD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally
controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85. [PMID: 17404349]
86. Saaristo T, Peltonen M, Keinanen-Kiukaanniemi S, Vanhala M, Saltevo J, Niskanen L, et al. National type 2 diabetes prevention programme in Finland:
FIN-D2D. Int J Circumpolar Health 2007;66:101-12. [PMID: 17515250]
87. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-64. [PMID: 16103469]
88. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003;26:3093-101. [PMID: 14578245]
89. Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care 2003;26:3102-10. [PMID: 14578246]
90. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-32. [PMID: 15738451]
91. Segal L, Dalton A, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promot Int 1998;13:197-210.
92. Caro JJ, Getsios D, Caro I, Klittich WS, O’Brien JA. Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med 2004;21:1229-36. [PMID: 15498090]
93. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin 2004;20 Suppl 1:S53-8. [PMID: 15324516]
94. Lindgren P, Lindstrom J, Tuomilehto J, Uusitupa M, Peltonen M, Jonsson B, et al. Lifestyle intervention to prevent diabetes in men and women with
impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care
2007;23:177-83. [PMID: 17493303]
95. Engelgau MM. Trying to predict the future for people with diabetes: a tough but important task [Editorial]. Ann Intern Med 2005;143:301-2. [PMID: 16103474]
96. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen
TR, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7. [PMID: 10597756]
97. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance:
modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004;26:304-21. [PMID: 15038953]
98. Adriaanse MC, Dekker JM, Spijkerman AM, Twisk JW, Nijpels G, van der Ploeg HM, et al. Diabetes-related symptoms and negative mood in participants of a targeted population-screening program for type 2 diabetes: The Hoorn Screening Study. Qual Life Res 2005;14:1501-9. [PMID: 16110930]
99. Adriaanse MC, Dekker JM, Spijkerman AM, Twisk JW, Nijpels G, van der Ploeg HM, et al. Health-related quality of life in the first year following diagnosis of Type 2 diabetes: newly diagnosed patients in general practice compared with screening-detected patients. The Hoorn Screening Study. Diabet Med 2004;21:1075-81. [PMID: 15384953]
100. Adriaanse MC, Snoek FJ, Dekker JM, Spijkerman AM, Nijpels G, Twisk JW, et al. No substantial psychological impact of the diagnosis of Type 2 diabetes following targeted population screening: The Hoorn Screening Study. Diabet Med 2004;21:992-8. [PMID: 15317604]
101. Adriaanse MC, Snoek FJ, Dekker JM, van der Ploeg HM, Heine RJ. Screening for Type 2 diabetes: an exploration of subjects' perceptions regarding
diagnosis and procedure. Diabet Med 2002;19:406-11. [PMID: 12027929]
102. Eborall H, Davies R, Kinmonth AL, Griffin S, Lawton J. Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007;335:490. [PMID: 17762000]
103. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007;335:486. [PMID: 17761995]
104. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Impact of diabetes screening on quality of life. Diabetes Care 2002;25:1022-6. [PMID: 12032109]
105. Farmer AJ, Doll H, Levy JC, Salkovskis PM. The impact of screening for Type 2 diabetes in siblings of patients with established diabetes. Diabet Med 2003;20:996-1004. [PMID: 14632700]
106. Farmer AJ, Doll HA. In a randomized trial, outcomes were not affected by intensive follow-up over 1 year. J Clin Epidemiol 2005;58:991-6. [PMID: 16168344]
107. Nichols GA, Brown JB. Functional status before and after diagnosis of type 2 diabetes. Diabet Med 2004;21:793-7. [PMID: 15209777]
108. Peel E, Parry O, Douglas M, Lawton J. Diagnosis of type 2 diabetes: a qualitative analysis of patients' emotional reactions and views about information provision. Patient Educ Couns 2004;53:269-75. [PMID: 15186863]
109. Skinner TC, Davies MJ, Farooqi AM, Jarvis J, Tringham JR, Khunti K. Diabetes screening anxiety and beliefs. Diabet Med 2005;22:1497-502. [PMID: 16241913]
110. Thoolen BJ, de Ridder DT, Bensing JM, Gorter KJ, Rutten GE. Psychological outcomes of patients with screen-detected type 2 diabetes: the influence of time since diagnosis and treatment intensity. Diabetes Care 2006;29:2257-62. [PMID: 17003303]
111. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance
or impaired fasting blood glucose. Cochrane Database Syst Rev 2006:CD005061. [PMID: 17054235]
112. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154-63. [PMID: 15616251]
113. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for
preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006:CD006257. [PMID: 17054288]
114. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828. [PMID: 15459003]
115. McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005;331:873. [PMID: 16183653]
116. Velazquez-Armenta EY, Han JY, Choi JS, Yang KM, Nava-Ocampo AA. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy 2007;26:51-66. [PMID: 17454218]
117. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005;26:2381-6. [PMID: 16081468]
118. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-38. [PMID: 16887404]
119. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;
295:306-13. [PMID: 16418466]
120. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007:CD002003. [PMID: 17253471]
121. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99. [PMID: 17638715]
122. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a
comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-94. [PMID: 17259518]
123. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst
Rev 2005:CD002966. [PMID: 16034881]
124. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006:CD002967. [PMID: 16437448]
125. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594-602. [PMID: 14638559]
126. Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25:2991-3026. [PMID: 14749143]
127. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ 2007;176:649-54. [PMID: 17325332]
128. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase
inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132-43. [PMID: 17072896]
129. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C. [PMID: 16581329]
130. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28:26-35. [PMID: 16490577]
131. Norris SL, Carson S, Roberts C. Drug Class Review on Thiazolidinediones. Portland, OR: Oregon Health & Science University; May 2006. Assessed on 8 April 2008 at http://ohsu.edu/drugeffectiveness/reports/final.cfm.
132. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007:CD006063. [PMID: 17636824]
133. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006: CD006060. [PMID: 17054272]
134. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95. [PMID: 17848653]
135. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005:CD004096. [PMID: 15674929]
136. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46. [PMID: 15809465]
137. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. [PMID: 17517853]
138. Wright AD, Cull CA, Macleod KM, Holman RR; for the UKPDS Group. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006;20:395-401. [PMID: 17070446]
139. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575-81. [PMID: 11955025]
140. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the
San Antonio heart study. Diabetes Care 2003;26:3153-9. [PMID: 14578254]
141. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention
and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6. [PMID: 14633807]
142. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068-74. [PMID: 17533210]
143. Greaves CJ, Stead JW, Hattersley AT, Ewings P, Brown P, Evans PH. A simple pragmatic system for detecting new cases of type 2 diabetes and impaired
fasting glycaemia in primary care. Fam Pract 2004;21:57-62. [PMID: 14760046]
144. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, et al. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005;28:2013-8. [PMID: 16043747]
145. Diabetes Prevention Program Research Group. Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care 2005;28:138-44. [PMID: 15616247]
146. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients
with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65. [PMID: 9742977]
147. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. [PMID: 15325833]
148. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44. [PMID: 8432214]
149. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002;359:881-4. [PMID: 11897304]
150. Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, et al. Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. Med Sci Sports Exerc 2006;38:826-32. [PMID: 16672833]
151. Dailey GE 3rd. Early insulin: an important therapeutic strategy [Editorial]. Diabetes Care 2005;28:220-1. [PMID: 15616256]
152. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86. [PMID: 8366922]
153. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53. [PMID: 16371630]
154. Zhang P, Engelgau MM, Valdez R, Benjamin SM, Cadwell B, Narayan KM. Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies. Diabetes Care 2003;26:2536-42. [PMID: 12941715]
155. Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC Jr, Ciocon JO, et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001;24:654-8. [PMID: 11315826]
156. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000;23:1619-29. [PMID: 11092283]
157. Fujimoto WY. Diabetes Prevention Program Research Group. Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care 2000;23 Suppl 2:B11-3. [PMID: 10860185]
158. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004;47:1519-27. [PMID: 15322749]
159. Lindstrom J, Eriksson JG, Valle TT, Aunola S, Cepaitis Z, Hakumaki M, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial.
J Am Soc Nephrol 2003;14:S108-13. [PMID: 12819313]
160. Laaksonen DE, Lindstrom J, Lakka TA, Eriksson JG, Niskanen L, Wikstrom K, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2005;54:158-65. [PMID: 15616024]
161. Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999;42:793-801. [PMID: 10440120]
162. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94. [PMID: 12876091]
163. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose
tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 1998;21:1720-5. [PMID: 9773737]
164. Torgerson JS, Arlinger K, Kappi M, Sjostrom L. Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (Xenical in the prevention of Diabetes in Obese Subjects) study experience. Control Clin Trials 2001;22:515-25. [PMID: 11578785]
Return to Contents
540 Gaither Road Rockville, MD 20850